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Abstract
Introduction: Both experimental and clinical data give convincing evidence to acute cardiac dysfunction as the
origin or a cofactor of weaning failure in patients with chronic obstructive pulmonary disease. Therefore, treatment
targeting the cardiovascular system might help the heart to tolerate more effectively the critical period of weaning.
This study aims to assess the hemodynamic, respiratory and clinical effects of nitroglycerin infusion in difficult-to-
wean patients with severe chronic obstructive pulmonary disease.
Methods: Twelve difficult-to-wean (failed ≥ 3 consecutive trials) chronic obstructive pulmonary disease patients,
who presented systemic arterial hypertension (systolic blood pressure ≥ 140mmHg) during weaning failure and
had systemic and pulmonary artery catheters in place, participated in this prospective, interventional, non-
randomized clinical trial. Patients were studied in two consecutive days, i.e., the first day without (Control day) and
the second day with (Study day) nitroglycerin continuous intravenous infusion starting at the beginning of the
spontaneous breathing trial, and titrated to maintain normal systolic blood pressure. Hemodynamic, oxygenation
and respiratory measurements were performed on mechanical ventilation, and during a 2-hour T-piece
spontaneous breathing trial. Primary endpoint was hemodynamic and respiratory effects of nitroglycerin infusion.
Secondary endpoint was spontaneous breathing trial and extubation outcome.
Results: Compared to mechanical ventilation, mean systemic arterial pressure, rate-pressure product, mean
pulmonary arterial pressure, and pulmonary artery occlusion pressure increased [from (mean ± SD) 94 ± 14, 13708
± 3166, 29.9 ± 4.8, and 14.8 ± 3.8 to 109 ± 20mmHg, 19856 ± 4877mmHg b/min, 41.6 ± 5.8mmHg, and 23.4 ± 7.4
mmHg, respectively], and mixed venous oxygen saturation decreased (from 75.7 ± 3.5 to 69.3 ± 7.5%) during
failing trials on Control day, whereas they did not change on Study day. Venous admixture increased throughout
the trial on both Control day and Study day, but this increase was lower on Study day. Whereas weaning failed in
all patients on Control day, nitroglycerin administration on Study day enabled a successful spontaneous breathing
trial and extubation in 92% and 88% of patients, respectively.
Conclusions: In this clinical setting, nitroglycerin infusion can expedite the weaning by restoring weaning-induced
cardiovascular compromise.
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In patients with chronic obstructive pulmonary disease
(COPD), the rate of weaning failure is high (>25%) and
results in prolonged mechanical ventilation that
increases both morbidity and mortality [1-4]. The most
common pathophysiologic cause of unsuccessful wean-
ing is thought to be failure of the respiratory muscle
pump [5]. However, some difficult-to-wean COPD
patients fail despite initial adequate ventilatory capaci-
ties. It has been suggested that the enormous workload
that these patients face during weaning may result in
cardiovascular distress and acute cardiac dysfunction [6].
Both experimental and clinical data give convincing
evidence of acute cardiac dysfunction as the origin or a
cofactor of weaning failure. Considerable negative
intrathoracic pressures developed at inspiration during
airway obstruction or pulmonary dynamic hyperinflation
or both increase venous return (that is, preload) and also
effectively increase left ventricular afterload [7,8]. Such
increases may not be tolerated by spontaneously breath-
ing patients with compromised heart function [7].
Patients with COPD have airway obstruction and com-
monly exhibit pulmonary dynamic hyperinflation [2-4],
and recent data [9] show that COPD itself is a powerful
independent risk factor for cardiovascular morbidity and
mortality, suggesting that occult cardiac dysfunction
could be frequent in patients with COPD. Indeed, cardio-
genic pulmonary edema was developed during weaning
of difficult-to-wean COPD patients with concomitant
cardiovascular disease [10]. Furthermore, in potentially-
able-to-wean COPD patients without obvious cardiac dis-
ease, a spontaneous breathing trial induced a significant
left ventricular ejection fraction reduction not explained
by a myocardial contractility decrease due to ischemia,
thus implying a weaning-induced increase in afterload
[11]. This increase in left ventricular afterload should be
higher in patients demonstrating systemic arterial hyper-
tension, which is quite frequent in COPD patients during
weaning failure [12,13]. Therefore, it could be suggested
that a treatment targeting the cardiovascular system
might help the heart to tolerate the critical period of
weaning more effectively. Vasodilators decrease the pres-
sure gradients for venous return and right and left ventri-
cular ejection and can affect left ventricular performance
in a manner similar to that of the increased intrathoracic
pressure [7]. To our knowledge, pharmaceutical interven-
tions with such agents in COPD patients who fail wean-
ing attempts have not been tested so far.
In the present study, we hypothesized that using nitro-
glycerin as the vasodilator agent to reduce venous return
and right and left ventricular afterload could facilitate
the weaning course in difficult-to-wean COPD patients.
Accordingly, we studied the hemodynamic, respiratory,
and clinical effects of nitroglycerin infusion during
weaning of severe COPD patients exhibiting systemic
arterial hypertension during repeatedly failing sponta-
neous breathing trials. The primary endpoint was hemo-
dynamic and respiratory effects of nitroglycerin infusion.
The secondary endpoint was spontaneous breathing trial
and extubation outcome. Preliminary results of this
study were presented at an international meeting [14].
Materials and methods
Patient selection
COPD patients who were intubated and mechanically
ventilated because of acute decompensation in the
intensive care unit of the Evangelismos Hospital,
Athens, Greece, were considered eligible for the study.
COPD was diagnosed on the basis of clinical history,
blood gases, chest radiographic findings, and previous
pulmonary function tests and hospital admissions. The
appropriate institutional ethics committee approved the
study, and informed written consent was obtained from
each patient’s close relative.
Inclusion criteria for study entry were the following:
(a) The underlying cause of acute decompensation of
COPD had resolved, and the primary physician had con-
sidered the patients ready to wean by performing spon-
taneous breathing trials. Criteria used in our institution
for not attempting such spontaneous breathing trials
[12] are similar to those of others [13]: known or sus-
pected increased intracranial pressure, unstable coronary
artery disease, heart rate of at least 120 beats per min-
ute, positive end-expiratory pressure of greater than
5c mH 2O, pulse oximetric measurement of arterial oxy-
gen saturation of less than 92%, fractional concentration
of inspired oxygen (FiO2) of greater than 0.6, infusion of
neuromuscular blocking drugs within the preceding 3
days, absent cough and gag reflex, or unresponsiveness
to noxious stimuli. (b) Patients were difficult to wean;
that is, they had failed at least three consecutive sponta-
neous breathing trials. (c) During spontaneous breathing
trial failure, patients presented respiratory distress and
systemic arterial hypertension, defined as systolic arterial
blood pressure of at least 140 mm Hg [15]. (d) Systemic
and pulmonary artery catheters inserted by the patients’
physicians as part of patient management to support the
weaning process were present. Exclusion criteria were
previous home care ventilation, unconsciousness or
need for sedation, and occurrence of an unstable coron-
ary episode (acute myocardial infarction or unstable
angina) and/or prior nitroglycerin use during current
intensive care unit admission/stay. All consecutive
patients fulfilling the criteria between January 2002 and
February 2007 were included in the study. During this
period, 52 patients with acute COPD decompensation
requiring invasive mechanical ventilation were admitted
to our center (2.6% of total admissions). Of these
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Page 2 of 11patients, 22 (42.3%) were difficult to wean, but only 12
patients fulfilled the criteria as 2 patients did not exhibit
systemic arterial hypertension during spontaneous
breathing trial failure, 2 patients had received nitrogly-
cerin because of a coronary episode, and 6 patients did
not have a pulmonary artery catheter in place during
weaning. During the study, a physician not involved in
the protocol was present to provide patient care.
Measurements
The hemodynamic and gas exchange measurements and
the calculations of hemodynamic and oxygenation vari-
ables were performed as previously described [12]. Cor-
rect positioning of the pulmonary artery catheter was
verified by chest radiography, blood gas sampling, and
waveform characteristics. The proximal and distal ports
of the pulmonary artery catheter and the systemic artery
catheter were connected to strain-gauge manometers
that provided continuous measurements of right atrial,
pulmonary, and systemic arterial pressures, respectively.
Pulmonary artery occlusion pressure was measured after
balloon inflation and wedging and was read at
end-expiration. Cardiac output was determined by ther-
modilution using an Opti-Q pulmonary artery catheter
connected to the Q-Vue continuous cardiac output
computer (Abbott Laboratories, Abbott Park, IL, USA).
For gas exchange measurements, partial pressures of
oxygen (PO2) and carbon dioxide (PCO2), pH, hemoglo-
bin oxygen saturation (SO2), and hemoglobin concentra-
tion (Hb) were determined from blood samples
anaerobically drawn from the arterial line and the distal
port of the pulmonary artery catheter. Samples were
immediately analyzed for blood gases (ABL 600; Radio-
meter Medical ApS, Brønshøj, Denmark).
The hemodynamic and gas exchange measurements
and the calculations of hemodynamic and oxygenation
variables were performed as previously described [12].
The rate-pressure product (RPP) was calculated as the
heart rate times systolic arterial blood pressure [13].
Airway pressure was measured at the external end of
the endotracheal or tracheostomy tube with a side port
connected to a pressure transducer (Validyne MP-45, ±
100 cm H2O; Validyne Engineering Corp., Northridge,
CA, USA). Distal to this side port, flow was measured
with a heated pneumotachograph (Hans Rudolph, Inc.,
Kansas City, MO, USA). The pressure drop across the
pneumotachograph was measured with a pressure trans-
ducer (Validyne MP-45, ± 2 cm H2O; Validyne Engi-
neering Corp.). Volume was obtained by integration of
the flow signal. Frequency was measured from the flow
signal. During a temporal disconnection from the venti-
lator before the spontaneous breathing trial, maximum
inspiratory pressure was measured as the maximal nega-
t i v ee x c u r s i o ni na i r w a yp ressure during 20-second
occlusion using a one-way valve [16]. The ratio of
frequency to tidal volume (index of rapid shallow
breathing) was calculated.
Protocol
Patients were placed in semirecumbent position while
they were ventilated in the assist-control mode with the
ventilator settings prescribed by the primary physician.
Patients then underwent a spontaneous breathing trial
via a T-piece circuit while receiving the same FiO2 as
during mechanical ventilation and gas humidification.
Trials lasted for 2 hours unless patients met at an earlier
time point; the criteria used to define spontaneous
breathing trial failure were the following [17]: tachypnea
(frequency of greater than 35 breaths per minute), arter-
ial hemoglobin oxygen saturation (SaO2)o fl e s st h a n
85% to 90% on pulse oximetry, tachycardia (heart rate
of greater than 120 to 140 beats per minute) or a sus-
tained change in heart rate of more than 20%, systolic
arterial blood pressure of greater than 180 to 200 mm
Hg or less than 90 mm Hg, arrhythmias, increased
accessory muscle use, diaphoresis, and onset or worsen-
ing of discomfort. The ability of the patient to remain
free of these criteria at the end of the trial was defined
as successful spontaneous breathing trial, and the
patient was extubated. Extubation was defined as suc-
cessful when spontaneous breathing was sustained for
more than 48 consecutive hours after the T-piece trial,
without development of any of the criteria of weaning
failure. Patients who met these criteria during the
2-hour trial or within 48 hours after extubation were
put back on assist-control mechanical ventilation, and
the weaning was defined as spontaneous breathing trial
failure or extubation failure, respectively. Weaning fail-
ure or success was judged by the primary physicians,
who were not the study investigators. After resumption
of mechanical ventilation, small-bolus infusions of pro-
pofol (0.5 to 1 mg/kg) were given if required in weaning
failure patients to achieve synchronization with the ven-
tilator, and patients were not disconnected from the
ventilator for the subsequent 24 hours.
Patients were studied on two consecutive days: the
first day without (Control day) and the second day
with (Study day) nitroglycerin. Nitroglycerin was admi-
nistered by continuous intravenous infusion starting at
the beginning of the spontaneous breathing trial, and
its dose was titrated to maintain normal systolic arter-
ial blood pressure (that is, 120 to 139 mm Hg) [15].
Whenever the spontaneous breathing trial failed,
administration of nitroglycerin was stopped at the time
of resumption of mechanical ventilation. In case of
trial success, nitroglycerin dose was gradually
decreased and ceased during the subsequent hours,
always titrated to systolic arterial blood pressure. No
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trol day and Study day.
Twelve-lead electrocardiograph and arterial saturation
were continuously recorded. Complete hemodynamic
and oxygenation measurements were performed during
mechanical ventilation, immediately before disconnec-
tion from the ventilator, and at 10 minutes (Start) and 2
hours (End) after the beginning of the spontaneous
breathing trial. Breath components were also measured
during mechanical ventilatio na n da t2m i n u t e s( S t a r t )
and 2 hours (End) after disconnection from the ventila-
tor. If the patient met the criteria of weaning failure
before the end of the trial, all measurements were taken
at the last minute of the trial (End).
Statistical analysis
Data are reported as mean ± standard deviation. Distri-
bution normality was tested by the Kolmogorov-Smir-
nov test. Comparison of data between mechanical
ventilation and the start and end of the spontaneous
breathing trial and between Control day and Study day
w a sd o n eb yu s i n gt w o - w a ya n a l y s i so fv a r i a n c e
(ANOVA) with repeated measurements across time, fol-
lowed by Scheffe test for post hoc comparisons. Differ-
ences between qualitative variables were assessed by
Fisher exact test. A P value of less than 0.05 was consid-
ered statistically significant.
Results
Twelve patients (9 men, 72 ± 7 years old) were included.
Demographic and clinical characteristics of the patients
are shown in Table 1. Patients had been 11 ± 6 days on
mechanical ventilation and had difficult weaning with
repeatedly failing weaning trials (6 ± 2). The causes of
acute decompensation and respiratory failure were acute
exacerbation (that is, an acute bout of pulmonary
inflammation involving increased secretion of purulent
sputum) in 9 patients, abdominal surgery in 2 patients,
and gastrointestinal hemorrhage in 1 patient. Three
patients had a history of intubation and mechanical ven-
tilation. Eleven patients were on long-term domiciliary
oxygen therapy. None was on home mechanical ventila-
tion. Eleven of the patients had pulmonary function
tests and blood gasses when stable in the months prior
to admission, and their forced vital capacity was
55.2% ± 18.3% predicted, forced expiratory volume in
one second was 27.4% ± 6.6% predicted, and partial
pressure of arterial carbon dioxide was 47 ± 8 mm Hg.
Echocardiography (transthoracic or transesophageal or
both) performed during mechanical ventilation 1 to 2
Table 1 Characteristics of the patients with chronic obstructive pulmonary disease
Patient Days
of MV
ET
ID,
mm
MIP,
cm
H2O
Cause of acute respiratory
failure/Prior cardiovascular
disease
Failed trial duration on
Control day, minutes
Weaning trial
outcome on Study
day
Extubation
outcome
ICU
outcome
1 15 9 -20 GI hemorrhage/
Hypertension
10 S S A
2 11 8 -40 AAA repair/
Hypertension, CAD
30 S S A
3 9 8.5 -25 Acute exacerbation/
None
15 S S A
4 5 8.5 -30 Acute exacerbation/
CP
30 S S A
52 8 8
a -25 Acute exacerbation/
Hypertension, CP
110 S NA D
6 8 8.5
a -30 Acute exacerbation/
None
60 S NA A
7 9 8.5
a -28 Acute exacerbation/
CAD
45 S NA A
8 6 8 -30 Acute exacerbation/
CAD
110 S S A
9 10 8 -40 Acute exacerbation/
Hypertension, CP
60 S S A
10 9 8 -50 Acute exacerbation/
Hypertension
30 S S A
11 12 7.5 -22 Gastrectomy/
None
30 F NA A
12 10 8.5 -30 Acute exacerbation/
CAD
55 S F D
a, tracheostomy tube; A, alive; AAA, abdominal aortic aneurysm; CAD, coronary artery disease; CP, cor pulmonale; D, died; ET, endotracheal tube; F, failure; GI,
gastrointestinal; ICU, intensive care unit; ID, internal diameter of tracheostomy tube; MIP, maximum inspiratory pressure; MV, mechanical ventilation; NA, not
applicable; S, success.
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erate left ventricular wall hypertrophy combined with
diastolic dysfunction in 4 patients and left ventricular
segmental wall motion abnormalities suggestive of pre-
vious inferior infarction in 3 patients [18]. Right ventricu-
lar free wall hypertrophy combined with right atrium and
ventricle dilation, with increase in the ratio between right
and left ventricular end diastolic volume but without
modification of septum kinetics, was detected in 3
patients [19]. No severe valvular disease was demon-
strated in any patient. Left ventricular ejection fraction
was 58% ± 8% (range of 46% to 71%) (normal value of
greater than 50%) [18,19]. At the time of the study, all
patients were hemodynamically stable during mechanical
ventilation without the use of any vasoactive agent. Seda-
tion (propofol 2 to 4 mg/kg per hour) had stopped for at
least 4 hours, and all patients had a Ramsay Sedation
Scale level 2. Patients were ventilated in the assist-control
mode with a Siemens 300 ventilator (Siemens, Solna,
Sweden) through a cuffed endotracheal (n =9 )o rt r a -
cheostomy (n = 3) tube and FiO2 of 0.4 to 0.5.
On Control day, all patients met the criteria of weaning
failure after 49 ± 33 minutes (Table 1) and were returned
to mechanical ventilation. In contrast, on Study day, 11
out of 12 patients (92%) tolerated the spontaneous breath-
ing trial (P < 0.001); one patient (number 11) failed this
trial because of severe bronchospasm. Except for the 3
patients with a tracheostomy tube, patients who tolerated
the spontaneous breathing trial (8 out of 11) were subse-
quently extubated. During the next 48 hours, 7 out of 8
extubated patients (88%) tolerated the spontaneous
breathing without development of any of the criteria of
weaning failure (extubation success), whereas 1 patient
(number 12) met these criteria and was re-intubated (extu-
bation failure). Therefore, 7 out of 9 endotracheally intu-
bated patients who were potentially able to be extubated
(that is, after excluding the 3 patients with tracheostomy)
were finally extubated and weaned successfully (78% ver-
sus 0% without nitroglycerin infusion, P = 0.002). On Con-
trol day, 4 patients demonstrated new onset of
electrocardiographic ischemic patterns, which were not
detected on Study day. Ten of the 12 patients survived
( T a b l e1 )a n dw e r ed i s c h a r g e df r o mt h ei n t e n s i v ec a r e
unit; two patients died of sepsis and multi-organ failure.
Two of the 10 patients who survived were discharged with
ventilatory support. Nitroglycerin was given at a dose of
40 to 600 μg/minute. After the spontaneous breathing
trial, nitroglycerin infusion was gradually reduced and
then ceased after 20 hours in all patients.
Hemodynamic variables
The effects of nitroglycerin on hemodynamics are shown
in Table 2 and Figure 1. No significant difference in any
of the hemodynamic variables was detected between the
Control day and Study day during mechanical ventilation.
From the start to the end of the spontaneous breathing
trial, mean arterial blood pressure, RPP, mean pulmonary
arterial pressure, and pulmonary artery occlusion pres-
sure increased compared with mechanical ventilation on
Control day but did not change on Study day (P =0 . 0 0 2 -
P < 0.001, two-way ANOVA of the interaction day ×
time). Right atrial pressure was constantly lower during
the trial on Study day compared with Control day (P =
0.001). Cardiac output increased during the trial on both
Control day and Study day. Systemic vascular resistance
did not change during the trial compared with mechani-
cal ventilation on Control day but decreased on Study
day. Similarly, pulmonary vascular resistance did not
change during the trial on Control day but decreased at
the end of the trial on Study day. Throughout the sponta-
neous breathing trial, right ventricular stroke work
increased compared with mechanical ventilation on Con-
trol day but did not change on Study day (P = 0.07).
Oxygenation
The effects of nitroglycerin on pulmonary and tissue
oxygenation are presented in Table 3 and Figure 2. Dur-
ing mechanical ventilation, oxygenation variables were
similar in Control day and Study day. During the spon-
taneous breathing trial, mixed venous oxygen saturation
decreased compared with mechanical ventilation on
Control day but did not change on Study day (P = 0.04).
Venous admixture increased throughout the trial on
both Control day and Study day, but the increase on
Study day was lower (P = 0.04). Oxygen extraction ratio
was similar during the spontaneous breathing trial on
Control day and Study day.
Pattern of breathing
Breath components are demonstrated in Table 3. No
difference in any of the breath components was detected
between Control day and Study day during mechanical
ventilation. Tidal volume decreased and frequency
increased throughout the trial compared with mechani-
cal ventilation on both Control day and Study day.
Index of rapid shallow breathing increased during the
trial on both Control day and Study day, but the
increase on Study day was lower (P = 0.03).
Adherence to protocol
The target of normal systolic arterial blood pressure on
Study day was achieved only partly in some patients and
their systolic blood pressure intermittently remained
higher than normal.
Discussion
The present study performed in difficult-to-wean COPD
patients exhibiting systemic arterial hypertension during
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following main findings: (a) systemic arterial pressure,
RPP, mean pulmonary arterial pressure, pulmonary
artery occlusion pressure, and right ventricular stroke
work increased and mixed venous oxygen saturation
decreased during failing trials, whereas nitroglycerin
infusion restored these changes; and (b) nitroglycerin
administration enabled a successful spontaneous breath-
ing trial and extubation in 92% and 88% of patients,
respectively.
Our results suggest that, in the clinical setting of the
present study, the use of nitroglycerin directed toward
the cardiovascular system can expedite weaning, pre-
sumably by alleviating acute cardiac dysfunction. Wean-
ing-induced acute cardiac dysfunction resulting in acute
pulmonary congestion is a known cause or cofactor of
weaning failure in predisposed COPD patients, particu-
larly in those with pre-existing cardiac disease [10,13];
its mechanisms of development are complex and include
increases in venous return and left ventricular preload,
myocardial ischemia, diastolic left ventricular dysfunc-
tion and an increase in left ventricular afterload
[10,13,20]. By restoring these mechanisms of develop-
ment of acute cardiac dysfunction, nitroglycerine admin-
istration proved to facilitate the weaning of our patients.
Indeed, 4 out of 12 patients demonstrated new onset of
electrocardiographic ischemic patterns on Control day,
and these patterns were not detected during nitrogly-
cerin administration on Study day. Weaning increases
myocardial oxygen demand by increasing sympathetic
activity, work of breathing, and left ventricular afterload
[7,8,10,11,13,20], thus inducing myocardial ischemia in
the setting of pre-existing coronary artery disease
[10,13,20]. A history of coronary artery disease was pre-
s e n ti n4o fo u r1 2p a t i e n t s( T a b l e1 ) ,a n d3o ft h e4
had findings of infarction on rest echocardiography. As
Table 2 Hemodynamics during weaning trials without (Control day) and with (Study day) nitroglycerin
Variable Mechanical ventilation Spontaneous breathing trial P value
a
Start End
HR, beats/minute Control day 91 ± 14 105 ± 14
b 111 ± 15
b 0.26
Study day 94 ± 16 105 ± 16
b 107 ± 13
b
sBP, mm Hg Control day 149 ± 19 179 ± 26
c 177 ± 25
c 0.002
Study day 144 ± 21 142 ± 23
d 135 ± 15
d
mBP, mm Hg Control day 94 ± 14 110 ± 21
b 109 ± 20
c < 0.001
Study day 91 ± 14 89 ± 15
d 85 ± 12
d
RPP, mm Hg beats/minute Control day 13,708 ± 3,166 19,041 ± 4,129
b 19,856 ± 4,877
b < 0.001
Study day 13,400 ± 2,637 14,738 ± 2,706
d 14,625 ± 2,383
d
PRA, mm Hg Control day 11.7 ± 3.2 13 ± 5.6 13.3 ± 5.8 0.001
Study day 10.6 ± 2.9 8.3 ± 3.5
d 8.7 ± 3.2
d
Mpap, mm Hg Control day 29.9 ± 4.8 40.3 ± 6.2
b 41.6 ± 5.8
b < 0.001
Study day 28.8 ± 5.9 28.3 ± 4.6
d 28.3 ± 3.9
d
Ppao, mm Hg Control day 14.8 ± 3.8 23.3 ± 7.6
b 23.4 ± 7.4
b < 0.001
Study day 14.8 ± 4.9 14.2 ± 3.7
d 14.8 ± 3.7
d
CO, L/minute Control day 6.6 ± 2 8.2 ± 2 8.7 ± 2.5
c 0.89
Study day 6.4 ± 2 8.3 ± 2.3
c 8.7 ± 2.7
b
SV, mL Control day 73.2 ± 22.7 77.8 ± 16.3 78.8 ± 19.5 0.69
Study day 70.3 ± 27.7 80.8 ± 26.8 81.3 ± 24.4
SVR, dyne/s per cm
5 Control day 1,084 ± 387 992 ± 300 931 ± 277 0.10
Study day 1,085 ± 361 827 ± 268
c 756 ± 252
b
PVR, dyne/s per cm
5 Control day 199 ± 69 176 ± 70 171 ± 51 0.28
Study day 192 ± 87 147 ± 57 137 ± 57
c
LVSW, g-m Control day 78.2 ± 26.4 91.9 ± 31.2 93.4 ± 37.1 0.62
Study day 73.5 ± 33.8 82.9 ± 35.6 78.3 ± 33.1
RVSW, g-m Control day 18.5 ± 9 28.8 ± 8.2
b 30.8 ± 11.2
b 0.07
Study day 17.6 ± 10.3 22.8 ± 12.1 22.3 ± 10.1
d
Values are presented as mean ± standard deviation.
aP value of the interaction (day × time) of the repeated-measures two-way analysis of variance comparison
between the Control day and Study day across time (that is, during mechanical ventilation and the 10th minute [Start] and last minute [End] of the spontaneous
breathing trial).
bP < 0.01 versus mechanical ventilation.
cP < 0.05 versus mechanical ventilation.
dP < 0.05 versus control day. CO, cardiac output; HR, heart rate;
LVSW, left ventricular stroke work; mBP mean arterial blood pressure; mPAP mean pulmonary arterial pressure; Ppao, pulmonary artery occlusion pressure;
PRA, right atrial pressure; PVR, pulmonary vascular resistance; RPP, rate-pressure product; RVSW, right ventricular stroke work; sBP, systolic arterial blood pressure;
SV, stroke volume; SVR systemic vascular resistance.
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COPD and coronary artery disease [9], several other
patients of ours, particularly those with a history of
hypertension, had an increased likelihood of occult
ischemic heart disease [13] (Table 1). In our study, RPP,
a global index of myocardial workload and oxygen
demand [21], increased during failing trials on Control
day, whereas nitroglycerin infusion restored this change,
thus suggesting a beneficial effect of nitroglycerin on
reducing myocardial oxygen demand and weaning-
induced myocardial ischemia.
Abnormal left ventricular diastolic function has been
reported frequently in COPD patients and may be
related to coexisting hypertension and left ventricular
hypertrophy and/or cardiac ischemia [22]. Potential
causes of acute pulmonary congestion during weaning
in patients with diastolic left ventricular dysfunction
include the weaning-induced increases in venous return
and left ventricular afterload, hypoxia, and tachycardia
[23]. In our study, 5 out of 12 patients had a history of
hypertension (Table 1) and 4 of the 5 demonstrated left
ventricular wall hypertrophy on rest echocardiography.
During failing weaning trials on Control day, these
patients as well as patients exhibiting myocardial
ischemia may have developed acute worsening of diasto-
lic left ventricular dysfunction with a consequent
increase in pulmonary artery occlusion pressure. By
decreasing systemic arterial pressure, left ventricular
afterload, and venous return and by preventing myocar-
dial ischemia and acute deterioration of diastolic left
ventricular dysfunction, nitroglycerine infusion should
have avoided the increase in pulmonary artery occlusion
pressure.
Another type of left ventricular diastolic dysfunction
in COPD patients is due to interventricular dependence
[24]. In COPD patients with pre-existing right ventricu-
lar disease associated with chronic pulmonary hyperten-
sion, weaning-induced increases in right ventricular
afterload and stress may occur because of hypoxemia,
hypercapnia combined with respiratory acidosis, and
worsening of intrinsic positive end-expiratory pressure
[10,25,26]. This phenomenon, together with a simulta-
neous increase in venous return, may lead to a marked
right ventricular enlargement during weaning, thus
impeding the diastolic filling of the left ventricle through
an interventricular dependence mechanism [10,25]. In
our study, most of the patients already met World
Health Organization criteria for pulmonary hypertension
Figure 1 Variations of systolic blood pressure (sBP) and pulmonary artery occlusion pressure (PAOP) during weaning trials. Individual
values of systolic blood pressure (sBP) (left) and pulmonary artery occlusion pressure (PAOP) (right) obtained on mechanical ventilation (MV) and
at the 10th minute (Start) and last minute (End) of the spontaneous breathing trial on Control day (upper panel) and Study day (lower panel).
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mm Hg) during mechanical ventilation (Table 2). The
fact that a substantial increase in mean pulmonary arter-
ial pressure on Control day was cancelled by nitrogly-
c e r i ni n f u s i o no nS t u d yd a ya n das i m i l a ri n c r e a s ei n
cardiac output occurred on both days (Figure 3) strongly
suggests that nitroglycerin infusion on Study day aban-
doned the increased right ventricular afterload on Con-
trol day [26]; attenuation of the increased right
ventricular stroke work by nitroglycerine has a similar
meaning (that is, decrease of the weaning-induced
increases in right ventricular afterload and stress). By
reducing the weaning-induced increases in right ventri-
cular afterload and venous return, nitroglycerin infusion
may have averted a noticeable right ventricular enlarge-
ment and acute left ventricular diastolic dysfunction
through interventricular dependence, thus contributing
to the decrease of the weaning-induced increase in pul-
monary artery occlusion pressure.
To the best of our knowledge, this is the first study in
which nitrates were given as vasodilator therapy in diffi-
cult-to-wean COPD patients in order to expedite the
weaning. However, nitroglycerin has been tested pre-
viously in stable or mechanically ventilated COPD
patients with chronic pulmonary hypertension [27-29];
in accordance with our findings, nitroglycerin decreased
mean pulmonary arterial pressure in stable mechanically
ventilated COPD patients [28] and decreased both mean
pulmonary arterial pressure and right ventricular stroke
work in mechanically ventilated COPD patients [29]. In
a recent anecdotal report, another type of vasodilator
therapy (that is, phosphodiesterase 5 inhibitors [sildena-
fil]) was used to facilitate weaning in three difficult-to-
wean COPD patients [30].
Potential limitations of the present study should be
pointed out. First, our population was highly selected:
the patients should have failed at least three consecutive
spontaneous breathing trials and demonstrated systemic
arterial hypertension during weaning failure before
being included in the study. This may have accounted
for the cardiovascular origin of or contribution to wean-
ing failure in our patients. Therefore, the message of
our study is not that the weaning failure in COPD
patients is primarily or necessarily related to
Table 3 Breath components and oxygenation during weaning trials without (Control day) and with (Study day)
nitroglycerin
Variable Mechanical ventilation Spontaneous breathing trial P value
a
Start End
VT, Ml Control day 617 ± 103 289 ± 123
b 298 ± 114
b 0.18
Study day 608 ± 88 343 ± 114
b 365 ± 73
b
Frequency, beats/minute Control day 16 ± 3.8 29 ± 7.7
b 29 ± 7.8
b 0.44
Study day 16 ± 4.1 25 ± 5
b 26 ± 5
b
VE, L/minute Control day 9.7 ± 2.9 8.1 ± 3.6 8.3 ± 3.3 0.51
Study day 9.7 ± 3.2 8.8 ± 3.3 9.4 ± 2.6
f/VT, beats/minute per liter Control day 26 ± 8 114 ± 48
b 108 ± 42
b 0.03
Study day 27 ± 7 82 ± 29
b,c 73 ± 19
b,c
PaO2, mm Hg Control day 130 ± 35 65 ± 18
b 66 ± 17
b 0.23
Study day 132 ± 35 85 ± 18
c,d 89 ± 23
c,d
PaCO2, mm Hg Control day 51 ± 10 69 ± 13
b 70 ± 13
b 0.20
Study day 49 ± 11 61 ± 13
b,c 64 ± 16
b
pHa Control day 7.41 ± 0.06 7.32 ± 0.07
b 7.30 ± 0.07
b 0.20
Study day 7.42 ± 0.05 7.34 ± 0.06
d 7.34 ± 0.07
b
SaO2, percentage Control day 98.3 ± 1.6 89.2 ± 6.2
b 88.8 ± 4.7
b 0.01
Study day 98.2 ± 1.5 95.3 ± 2.2
c 94.9 ± 2.2
c
SvO2, percentage Control day 75.7 ± 3.5 67.3 ± 7.2
d 69.3 ± 7.5
d 0.04
Study day 73 ± 4.1 72.3 ± 4.3
c 74.6 ± 4.3
c
Qs/Qt, percentage Control day 15.0 ± 6.0 37.8 ± 17.8
b 39.5 ± 13.8
b 0.04
Study day 14.3 ± 5.9 25.7 ± 6.6
c 28.5 ± 8.1
d
O2ER, percentage Control day 24.4 ± 3.3 24.7 ± 8.4 22.9 ± 8.5 0.32
Study day 27 ± 4.1 24.8 ± 4.4 22.1 ± 4.5
Values are presented as mean ± standard deviation.
aP value of the interaction (day × time) of the repeated-measures two-way analysis of variance comparison
between the Control day and Study day across time (that is, during mechanical ventilation, the second minute [for breath components] or 10th minute [for
oxygenation variables] [Start], and the last minute [End] of the spontaneous breathing trial).
bP < 0.001 versus mechanical ventilation.
cP < 0.05 versus control
day.
dP < 0.05 versus mechanical ventilation. f/VT, frequency/tidal volume (index of rapid shallow breathing); O2ER, oxygen extraction ratio; PaCO2, arterial carbon
dioxide partial pressure; PaO2, arterial oxygen partial pressure; pHa, arterial pH; Qs/Qt, venous admixture; SaO2, arterial oxygen saturation; SvO2, mixed venous
oxygen saturation; VE, minute ventilation; VT, tidal volume.
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Page 8 of 11Figure 2 Variations of arterial oxygen saturation (SaO2) and mixed venous oxygen saturation (SaO2)d u r i n gw e a n i n gt r i a l s .I n d i v i d u a l
values of arterial oxygen saturation (SaO2) (left) and mixed venous oxygen saturation (SvO2) (right) obtained on mechanical ventilation (MV) and
at the 10th minute (Start) and last minute (End) of the spontaneous breathing trial on Control day (upper panel) and Study day (lower panel).
Figure 3 Mean pulmonary arterial pressure and mean arterial blood pressure versus cardiac output during mechanical ventilation
(circles) and at the start (triangles) and end (squares) of spontaneous breathing trials on Control day (closed symbols) and Study day
(open symbols). Substantial increases in mean pulmonary arterial pressure and mean arterial blood pressure on Control day were cancelled by
nitroglycerin infusion on Study day and a similar increase in cardiac output occurred on both days, strongly suggesting that nitroglycerin
infusion on Study day abandoned the increased right and left ventricular afterload on Control day.
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Page 9 of 11cardiovascular problems. Second, the number of patients
studied is relatively small, despite the 5-year study dura-
tion and inclusion of consecutive patients; nowadays,
only limited numbers of COPD patients require invasive
mechanical ventilation since acute decompensation is
frequently managed successfully by non-invasive
mechanical ventilation, and our strict inclusion criteria
resulted in high patient selection. However, each patient
was studied twice, thus serving as his or her own con-
trol, and hemodynamic and respiratory responses to dis-
continuation of mechanical ventilation either with or
without nitroglycerin infusion were homogeneous as
indicated by the small standard deviations and the nor-
mal distribution of most continuous variables that
allowed use of parametric statistical tests. Third, a non-
randomized design was applied and potentially this
could have resulted in an order effect. Indeed, it cannot
be excluded that the hemodynamic and outcome results
were related not only to the administration of nitrates
but also to the fact that the Study day was 24 hours
after the Control day. Fourth, we did not measure eso-
phageal pressure to assess a transmural value of pul-
monary artery occlusion pressure, which could be lower
than that at end-expiration in patients actively contract-
ing their expiratory muscles during expiration. Indeed,
in four patients, the pulmonary artery occlusion pres-
sure was increased on mechanical ventilation before the
start of the spontaneous breathing trial. In these
patients, the attending physicians considered that hyper-
inflation or active expiration or both contributed to this
increase.
Conclusions
The present non-randomized study performed in diffi-
cult-to-wean COPD patients exhibiting systemic arterial
hypertension during failing spontaneous breathing trials
demonstrated that nitroglycerin infusion can expedite
the weaning, most likely by restoring the weaning-
induced increases in venous return and left ventricular
preload, myocardial ischemia, diastolic left ventricular
dysfunction and the increase in left ventricular afterload,
thus alleviating the weaning-induced acute cardiac dys-
function. However, because of high patient selection, the
message of this study is not that weaning failure in
COPD patients is primarily or necessarily related to
weaning-induced acute cardiovascular problems.
Key messages
￿ Nitroglycerin infusion can expedite the weaning in dif-
ficult-to-wean chronic obstructive pulmonary disease
(COPD) patients exhibiting systemic arterial hyperten-
sion during failing spontaneous breathing trials.
￿ Nitroglycerin infusion most likely works by alleviat-
ing the weaning-induced acute cardiac dysfunction.
￿ Because of high patient selection, the message of this
study is not that weaning failure in COPD patients is
primarily or necessarily related to weaning-induced
acute cardiovascular problems.
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